OBJECTIVES: To quantify hospitalisations among adult R/R ALL patients treated with current salvage chemotherapies in Italy. METHODS: Adult patients hospitalised from 2003–2014 for Ph-negative R/R ALL were included. Eligible patients were relapsed with first remission lasting less than 12 months, relapsed after first salvage therapy, relapsed any time after HSCT or refractory to primary induction or salvage therapy. Data were collected from the index date (first diagnosis of R/R ALL) until death or loss to follow-up. The salvage chemotherapy period encompassed the first chemotherapy after the index date to the earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy dose plus 30 days. The primary endpoint was the percent of time in the hospital during the salvage chemotherapy period. Key secondary endpoints were number of hospitalisations and length of hospital stay. Hospitalisations associated with HSCT were excluded. Results are presented as mean (SD) unless indicated. RESULTS: Twenty-two patients were included, with a mean age of 44 (18) years. After the index date, 19 patients died and 8 patients received a HSCT. During the chemotherapy salvage period, patients spent a mean of 56% (95% CI: 46%-69%) of their time in the hospital. There were a mean of 2.2 (1.5) inpatient hospitalisations, 3.2 (6.2) day stays, and 1.6 (3.0) outpatient visits per patient, and the mean length of inpatient hospitalisation was 20.0 (20.0) days. From the index date to death, there were a mean of 2.8 (1.4) inpatient hospitalisations, 4.7 (7.3) day stays, and 4.6 (7.4) outpatient visits per patient and the mean length of inpatient hospitalisation was 19.0 (19.0) days. CONCLUSIONS: Adult patients receiving salvage chemotherapy for R/R ALL in Italy spend more than half their time in the hospital. Costs of hospitalisations will be presented.